RU2017106891A - Биомаркеры поликистозной болезни почек и пути их применения - Google Patents
Биомаркеры поликистозной болезни почек и пути их применения Download PDFInfo
- Publication number
- RU2017106891A RU2017106891A RU2017106891A RU2017106891A RU2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A
- Authority
- RU
- Russia
- Prior art keywords
- pkd
- patient
- protein
- cyclin
- kinase
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title claims 39
- 239000000090 biomarker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 27
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 18
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims 18
- 108050006400 Cyclin Proteins 0.000 claims 17
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 17
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 17
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims 17
- 102000003861 Ribosomal protein S6 Human genes 0.000 claims 13
- 108090000221 Ribosomal protein S6 Proteins 0.000 claims 13
- 108091008611 Protein Kinase B Proteins 0.000 claims 12
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 12
- 108010058546 Cyclin D1 Proteins 0.000 claims 11
- 108010058545 Cyclin D3 Proteins 0.000 claims 11
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 11
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims 11
- -1 5-fluoro-4- (4 - ((2-methoxyethoxy) methyl) phenyl) pyrimidin-2-yl Chemical group 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 102000011260 Retinoblastoma Binding Proteins Human genes 0.000 claims 7
- 108010023377 Retinoblastoma Binding Proteins Proteins 0.000 claims 7
- 102000004046 Caspase-2 Human genes 0.000 claims 6
- 108090000552 Caspase-2 Proteins 0.000 claims 6
- 239000013060 biological fluid Substances 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 108091005981 phosphorylated proteins Proteins 0.000 claims 6
- 201000000582 Retinoblastoma Diseases 0.000 claims 5
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 claims 5
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 claims 4
- 210000001808 exosome Anatomy 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- UMWIMNNPYBWNRY-XMMPIXPASA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[4-[4-(2-methoxyethoxy)phenyl]phenyl]propan-2-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=C(C(C)(C)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 UMWIMNNPYBWNRY-XMMPIXPASA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033031P | 2014-08-04 | 2014-08-04 | |
| US62/033,031 | 2014-08-04 | ||
| PCT/US2015/043497 WO2016022500A2 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017106891A true RU2017106891A (ru) | 2018-09-06 |
| RU2017106891A3 RU2017106891A3 (enExample) | 2019-03-14 |
Family
ID=54035292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106891A RU2017106891A (ru) | 2014-08-04 | 2015-08-03 | Биомаркеры поликистозной болезни почек и пути их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10871495B2 (enExample) |
| EP (1) | EP3177932B1 (enExample) |
| JP (2) | JP6730252B2 (enExample) |
| KR (1) | KR20170033436A (enExample) |
| CN (1) | CN106716136B (enExample) |
| AU (1) | AU2015301278A1 (enExample) |
| BR (1) | BR112017002003A2 (enExample) |
| CO (1) | CO2017001596A2 (enExample) |
| MX (1) | MX2017001648A (enExample) |
| RU (1) | RU2017106891A (enExample) |
| SG (1) | SG11201700290SA (enExample) |
| WO (1) | WO2016022500A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895963B2 (ja) | 2015-11-18 | 2021-06-30 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE402257T1 (de) | 1999-05-24 | 2008-08-15 | Avi Biopharma Inc | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit |
| CA2574709A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| WO2010141862A2 (en) | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| ES2606140T3 (es) | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| US10478446B2 (en) | 2012-07-03 | 2019-11-19 | Fondazione Centro San Raffaele Office Of Biotechnology Transfer | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
-
2015
- 2015-08-03 RU RU2017106891A patent/RU2017106891A/ru not_active Application Discontinuation
- 2015-08-03 JP JP2017506291A patent/JP6730252B2/ja active Active
- 2015-08-03 EP EP15757363.5A patent/EP3177932B1/en active Active
- 2015-08-03 WO PCT/US2015/043497 patent/WO2016022500A2/en not_active Ceased
- 2015-08-03 CN CN201580053081.4A patent/CN106716136B/zh active Active
- 2015-08-03 AU AU2015301278A patent/AU2015301278A1/en not_active Abandoned
- 2015-08-03 SG SG11201700290SA patent/SG11201700290SA/en unknown
- 2015-08-03 KR KR1020177005740A patent/KR20170033436A/ko not_active Withdrawn
- 2015-08-03 MX MX2017001648A patent/MX2017001648A/es unknown
- 2015-08-03 BR BR112017002003A patent/BR112017002003A2/pt not_active Application Discontinuation
- 2015-08-03 US US15/501,496 patent/US10871495B2/en active Active
-
2017
- 2017-02-17 CO CONC2017/0001596A patent/CO2017001596A2/es unknown
-
2020
- 2020-07-01 JP JP2020113693A patent/JP7005695B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020170013A (ja) | 2020-10-15 |
| BR112017002003A2 (pt) | 2017-12-12 |
| SG11201700290SA (en) | 2017-02-27 |
| MX2017001648A (es) | 2017-04-27 |
| WO2016022500A3 (en) | 2016-04-07 |
| US10871495B2 (en) | 2020-12-22 |
| JP2017525955A (ja) | 2017-09-07 |
| EP3177932A2 (en) | 2017-06-14 |
| JP7005695B2 (ja) | 2022-02-04 |
| RU2017106891A3 (enExample) | 2019-03-14 |
| AU2015301278A1 (en) | 2017-02-09 |
| CO2017001596A2 (es) | 2017-05-19 |
| CN106716136B (zh) | 2020-06-23 |
| EP3177932B1 (en) | 2021-07-14 |
| US20170227551A1 (en) | 2017-08-10 |
| CN106716136A (zh) | 2017-05-24 |
| KR20170033436A (ko) | 2017-03-24 |
| JP6730252B2 (ja) | 2020-07-29 |
| WO2016022500A2 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Mouse models of intracerebral hemorrhage in ventricle, cortex, and hippocampus by injections of autologous blood or collagenase | |
| Tseng et al. | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | |
| Pons et al. | VEGF improves survival of mesenchymal stem cells in infarcted hearts | |
| Paulsson et al. | Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma | |
| Leung et al. | Evidence for the existence of triple‐negative variants in the MCF‐7 breast cancer cell population | |
| Stessin et al. | The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma—experience from the SEER database | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| Amajoyi et al. | Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens | |
| Signorovitch et al. | Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis | |
| Loh et al. | Extracranial oligometastatic renal cell carcinoma: current management and future directions | |
| EA201892542A1 (ru) | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 | |
| Karaman et al. | Factors affecting postoperative mortality in patients older than 65 years undergoing surgery for hip fracture | |
| JP2016528914A5 (enExample) | ||
| Wang et al. | Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors | |
| JP2017525955A5 (enExample) | ||
| Brown et al. | Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development | |
| JP2019502902A5 (enExample) | ||
| BR112017002003A2 (pt) | biomarcadores de doença renal policística e usos dos mesmos | |
| KR102598667B1 (ko) | 강직성 척추염 환자에 대한 생물학적제제의 반응성 예측 방법 및 분석 장치 | |
| Song et al. | Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era | |
| Raphael et al. | Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution | |
| Moskowitz et al. | Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: No… Well Yes,… But Maybe Not for Long | |
| Giunta et al. | Clinical markers predictive of primary inefficacy: a “real life” retrospective study in psoriatic patients treated with etanercept | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| Markopoulos | IMPACT OF THE 21-GENE RECURRENCE SCORE ASSAY ON TREATMENT DECISION IN EARLY BREAST CANCER (EBC) PATIENTS WITH FAVORABLE PROGNOSTIC FACTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190627 |